Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press11710.17650/1994-4098-2012-0-3-4-61-72MAMMOLOGY. TREATMENTМАММОЛОГИЯ. ЛЕЧЕНИЕChoice of adjuvant drug therapy on the basis of the molecular classification of breast cancerВыбор адъювантной лекарственной терапии на основе молекулярной классификации рака молочной железыBesovaN. S.БесоваН. С.
Russian Federation
besovans@mail.ruN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва240920123-4617224072014240720142012https://ojrs.abvpress.ru/ojrs/article/view/117

Molecular genetic analysis identified some biological subtypes of breast cancer (BC): luminal A, luminal B, HER2 positive, and basal-like (including triple negative). The surrogate clinical and morphological criteria including the immunohistochemical determination of estrogen and progesterone receptors, the hyperexpression and/or amplification of HER2, Ki-67, or tumor grade (G) are used to identify the biological subtypes of BC in clinical practice. The biological subtypes are distinguished by their biological course and susceptibility to various systemic treatments, which requires different therapeutic tactics. The paper presents tactics of adjuvant therapy for BC in relation to its biological subtype according to the recommendations of the 12th St. Gallen International Breast Cancer Conference (2011) and considers the place of taxans.

На основе молекулярно-генетического анализа выделено несколько биологических подтипов рака молочной железы (РМЖ): люминальный А, люминальный В, HER2-позитивный и базальноподобный (включая и трижды негативный: ТН РМЖ). В клинической практике для идентификации биологических подтипов РМЖ используются суррогатные клинико-морфологические критерии, включающие иммуногистохимическое определение рецепторов эстрогена и прогестерона, гиперэкспрессии и/или амплификации HER2, Ki-67 или степени злокачественности опухоли (G). Биологические подтипы различаются по биологическому течению и чувствительности к разным видам системного лечения, что требует различной терапевтической тактики. В статье представлена тактика адъювантной терапии РМЖ в зависимости от биологического подтипа опухоли согласно рекомендациям 12-й Международной конференции по лечению РМЖ (Сант-Галлен, 2011 г.), рассмотрено место таксанов.

breast cancerbiological subtypesadjuvant chemotherapytaxansрак молочной железыбиологические подтипыадъювантная химиотерапиятаксаны1. Perou C.M., Sorlie T., Eisen M.B. et al. Molecular portraits of human breast tumours.Nature 2000;406:747−52.Perou C.M., Sorlie T., Eisen M.B. et al. Molecular portraits of human breast tumours.Nature 2000;406:747−52.2. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5−23.Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5−23.3. Parker J.S., Mullins M., Cheang M.C. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160−7.Parker J.S., Mullins M., Cheang M.C. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160−7.4. Nielsen T.O., Hsu F.D., Jensen K. et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367−74.Nielsen T.O., Hsu F.D., Jensen K. et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367−74.5. Blows F.M., Driver K.E., Schmidt M.K. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7:e1000279.Blows F.M., Driver K.E., Schmidt M.K. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7:e1000279.6. Hugh J., Hanson J., Cheang M.C. et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol 2009; 27:1168−76.Hugh J., Hanson J., Cheang M.C. et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol 2009; 27:1168−76.7. Cheang M.C., Chia S.K, Voduc D. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736−50.Cheang M.C., Chia S.K, Voduc D. et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736−50.8. Millikan R.C., Newman B., Tse C.K. et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109:123−39.Millikan R.C., Newman B., Tse C.K. et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109:123−39.9. Phipps A.I., Chlebowski R.T., Prentice R. et al. Body size, physical activity, and risk of triple-negative and estrogen receptor- positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011;20:454−63.Phipps A.I., Chlebowski R.T., Prentice R. et al. Body size, physical activity, and risk of triple-negative and estrogen receptor- positive breast cancer. Cancer Epidemiol Biomarkers Prev 2011;20:454−63.10. Phipps A.I., Buist D.S., Malone K.E. et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011; 22:399−405.Phipps A.I., Buist D.S., Malone K.E. et al. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011; 22:399−405.11. Liedtke C., Mazouni C., Hess K.R. et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275−81.Liedtke C., Mazouni C., Hess K.R. et al. Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275−81.12. Dignam J.J., Dukic V., Anderson S.J. et al. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 2009;116:595−602.Dignam J.J., Dukic V., Anderson S.J. et al. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 2009;116:595−602.13. Aebi S., Sun Z., Braun D. et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol 2011 [epub ahead of print 31 January 2011] doi:10.1093/annonc/mdq754.Aebi S., Sun Z., Braun D. et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol 2011 [epub ahead of print 31 January 2011] doi:10.1093/annonc/mdq754.14. Albain K.S., Barlow W.E., Shak S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11:55−65.Albain K.S., Barlow W.E., Shak S. et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11:55−65.15. Nguyen P.L., Taghian A.G., Katz M.S. et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26:2373−8.Nguyen P.L., Taghian A.G., Katz M.S. et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26:2373−8.16. Wo J.Y., Taghian A.G., Nguyen P.L. et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys 2010;77:188−96.Wo J.Y., Taghian A.G., Nguyen P.L. et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys 2010;77:188−96.17. Tang G., Shak S., Paik S. et al. Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and Adjuvant for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011;127:133−42.Tang G., Shak S., Paik S. et al. Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and Adjuvant for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011;127:133−42.18. Hugh J., Hanson J., Cheang M.C. et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27:1168−76.Hugh J., Hanson J., Cheang M.C. et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27:1168−76.19. Goldhirsch A., Wood W.C., Coates A.S. et al. Strategies for subtypes−dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology Advance Access published June 27,2011;1−12.Goldhirsch A., Wood W.C., Coates A.S. et al. Strategies for subtypes−dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology Advance Access published June 27,2011;1−12.20. Citron M.L., Berry D.A., Cirrincione C. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431−9.Citron M.L., Berry D.A., Cirrincione C. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431−9.21. Henderson I.C., Berry D.A., Demetri G.D. et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976−83.Henderson I.C., Berry D.A., Demetri G.D. et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976−83.22. Mamounas E., Bryant J., Lembersky B. et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23:3686−96.Mamounas E., Bryant J., Lembersky B. et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23:3686−96.23. Gianni L., Baselga J., Eiermann W. et al Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009; 27:2474−81.Gianni L., Baselga J., Eiermann W. et al Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009; 27:2474−81.24. Buzdar A.U., Singletary S.E., Valero V. et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002;8:1073−9.Buzdar A.U., Singletary S.E., Valero V. et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002;8:1073−9.25. Albert J.M., Buzdar A.U., Guzman R. et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat 2011 Jul; 128(2):421−7.Albert J.M., Buzdar A.U., Guzman R. et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat 2011 Jul; 128(2):421−7.26. Sparano J.A., Wang M., Martino S. et al. Phase III study of doxorubicin cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk nodenegative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. San Antonio Breast Cancer Symposium, San Antonio, 2005.Sparano J.A., Wang M., Martino S. et al. Phase III study of doxorubicin cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk nodenegative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. San Antonio Breast Cancer Symposium, San Antonio, 2005.27. Martin M., Rodriguez-Lescure A., Ruiz A. et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclo- phosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 2008;100:805−14.Martin M., Rodriguez-Lescure A., Ruiz A. et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclo- phosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 2008;100:805−14.28. Loesch D., Greco F.A., Senzer N.N. et al. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol 2010 Jun 20; 28(18):2958−65.Loesch D., Greco F.A., Senzer N.N. et al. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol 2010 Jun 20; 28(18):2958−65.29. Martín M., Rodríguez-Lescure A., Ruiz A. et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2010 Aug;123(1):149−57.Martín M., Rodríguez-Lescure A., Ruiz A. et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2010 Aug;123(1):149−57.30. Laporte S., Jones S., Chapelle C. et al. Consistency of effect of docetaxel containing adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: Meta-analysis of 12 randomized clinical trials [abstract 605]. Presented at the 2009 San Antonio Breast Cancer Symposium, San Antonio, Texas, 2009.Laporte S., Jones S., Chapelle C. et al. Consistency of effect of docetaxel containing adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: Meta-analysis of 12 randomized clinical trials [abstract 605]. Presented at the 2009 San Antonio Breast Cancer Symposium, San Antonio, Texas, 2009.31. Swain S.M. Chemotherapy: updates and new perspectives. The Oncologist 2011; 16(1):30−9.Swain S.M. Chemotherapy: updates and new perspectives. The Oncologist 2011; 16(1):30−9.32. Jones S., Holmes F.A., O’Shaughnessy J. et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicinand cyclophosphamide: 7-Year follow-up of US Oncology research trial 9735. J Clin Oncol 2009;27:1177−83.Jones S., Holmes F.A., O’Shaughnessy J. et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicinand cyclophosphamide: 7-Year follow-up of US Oncology research trial 9735. J Clin Oncol 2009;27:1177−83.33. Penault-Llorca F., André F., Sagan C. et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor- positive breast cancer. J Clin Oncol 2009; 27:2809−15.Penault-Llorca F., André F., Sagan C. et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor- positive breast cancer. J Clin Oncol 2009; 27:2809−15.